DaVita Inc. (NYSE:DVA) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. raised its holdings in shares of DaVita Inc. (NYSE:DVA) by 6,158.3% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 77,979 shares of the company’s stock after acquiring an additional 76,733 shares during the quarter. Federated Hermes Inc.’s holdings in DaVita were worth $8,169,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Daiwa Securities Group Inc. lifted its position in shares of DaVita by 3.7% during the fourth quarter. Daiwa Securities Group Inc. now owns 4,802 shares of the company’s stock worth $503,000 after purchasing an additional 171 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of DaVita by 28.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,657 shares of the company’s stock worth $10,021,000 after purchasing an additional 21,205 shares in the last quarter. Everence Capital Management Inc. acquired a new position in shares of DaVita during the fourth quarter worth $393,000. LifePlan Financial LLC acquired a new position in shares of DaVita during the fourth quarter worth $224,000. Finally, Sippican Capital Advisors increased its stake in shares of DaVita by 19.0% in the fourth quarter. Sippican Capital Advisors now owns 15,618 shares of the company’s stock worth $1,636,000 after buying an additional 2,496 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on DVA shares. Barclays started coverage on shares of DaVita in a research note on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price target for the company. UBS Group lifted their price target on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Truist Financial boosted their target price on shares of DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday, February 20th. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 16th. Finally, TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $118.50.

DaVita Price Performance

Shares of NYSE DVA opened at $132.75 on Thursday. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $141.54. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65. The company has a market capitalization of $11.64 billion, a price-to-earnings ratio of 17.94, a PEG ratio of 1.19 and a beta of 1.04. The firm has a 50-day moving average of $131.63 and a two-hundred day moving average of $110.00.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.53 by $0.34. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The company had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.01 billion. During the same period in the prior year, the company earned $1.11 EPS. DaVita’s revenue was up 7.8% on a year-over-year basis. As a group, analysts expect that DaVita Inc. will post 9.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now owns 488,697 shares in the company, valued at approximately $61,629,578.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other DaVita news, insider James O. Hearty sold 26,164 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the sale, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The disclosure for this sale can be found here. In the last quarter, insiders have sold 134,540 shares of company stock worth $16,551,071. Company insiders own 1.40% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.